300 related articles for article (PubMed ID: 12666097)
1. Bioenergetic approaches for neuroprotection in Parkinson's disease.
Beal MF
Ann Neurol; 2003; 53 Suppl 3():S39-47; discussion S47-8. PubMed ID: 12666097
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection for Parkinson's disease.
LeWitt PA
J Neural Transm Suppl; 2006; (71):113-22. PubMed ID: 17447422
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic role of coenzyme Q(10) in Parkinson's disease.
Shults CW
Pharmacol Ther; 2005 Jul; 107(1):120-30. PubMed ID: 15963354
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.
Ogawa O; Zhu X; Perry G; Smith MA
Sci Aging Knowledge Environ; 2002 Oct; 2002(41):pe16. PubMed ID: 14603007
[TBL] [Abstract][Full Text] [Related]
5. Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine.
Virmani A; Gaetani F; Binienda Z
Ann N Y Acad Sci; 2005 Aug; 1053():183-91. PubMed ID: 16179522
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
7. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.
Tarnopolsky MA; Beal MF
Ann Neurol; 2001 May; 49(5):561-74. PubMed ID: 11357946
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria.
Osborne NN
Prog Brain Res; 2008; 173():339-52. PubMed ID: 18929120
[TBL] [Abstract][Full Text] [Related]
9. Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
Beal MF
Ann N Y Acad Sci; 2003 Jun; 991():120-31. PubMed ID: 12846981
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
Zaitone SA; Abo-Elmatty DM; Shaalan AA
Pharmacol Biochem Behav; 2012 Jan; 100(3):347-60. PubMed ID: 21958946
[TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q treatment of neurodegenerative diseases of aging.
Galpern WR; Cudkowicz ME
Mitochondrion; 2007 Jun; 7 Suppl():S146-53. PubMed ID: 17485247
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective actions of coenzyme Q10 in Parkinson's disease.
Sharma S; Kheradpezhou M; Shavali S; El Refaey H; Eken J; Hagen C; Ebadi M
Methods Enzymol; 2004; 382():488-509. PubMed ID: 15047119
[No Abstract] [Full Text] [Related]
13. Targeting cellular energy production in neurological disorders.
Baker SK; Tarnopolsky MA
Expert Opin Investig Drugs; 2003 Oct; 12(10):1655-79. PubMed ID: 14519086
[TBL] [Abstract][Full Text] [Related]
14. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease.
Cai X; Jia H; Liu Z; Hou B; Luo C; Feng Z; Li W; Liu J
J Neurosci Res; 2008 Dec; 86(16):3622-34. PubMed ID: 18709653
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
Beal MF
J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
[TBL] [Abstract][Full Text] [Related]
16. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate.
Beal MF; Henshaw DR; Jenkins BG; Rosen BR; Schulz JB
Ann Neurol; 1994 Dec; 36(6):882-8. PubMed ID: 7998775
[TBL] [Abstract][Full Text] [Related]
17. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10.
Somayajulu M; McCarthy S; Hung M; Sikorska M; Borowy-Borowski H; Pandey S
Neurobiol Dis; 2005 Apr; 18(3):618-27. PubMed ID: 15755687
[TBL] [Abstract][Full Text] [Related]
18. ALS lessons learned from other neurological diseases. Parkinson's disease.
Fahn S
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():26-30. PubMed ID: 15512865
[No Abstract] [Full Text] [Related]
19. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
Löhle M; Reichmann H
J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
[TBL] [Abstract][Full Text] [Related]
20. Why have we failed to achieve neuroprotection in Parkinson's disease?
Olanow CW; Kieburtz K; Schapira AH
Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
